PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Argenx spotlights myasthenia gravis with patient-shot docuseries

Energy, exercise, family time and even a job—those are the real-life costs of myasthenia gravis (MG) highlighted in Argenx’s new docuseries about the autoimmune disorder.

“Just like they adapt and change and are resilient with their disease, they did the same thing in filming this,” Argenx Chief Operating Officer Keith Woods said.

A trailer for the series is out now, with the online premiere set for a Nov. 17 debut on Argenx’s MG United website. The 20-minute documentary about Vanetta has already been chosen as a local short film in the upcoming Chicago International Film Festival.

Director Ben Strang and production company Sarofsky Films pored over the hundreds of hours of footage sent by the patients and their families to piece together the finished movies.

The docuseries process began with more than 100 people with MG who were interested in participating.

While the three people featured all have MG, their stories are so different because the unseen disease impacts everyone differently, Woods noted.

“No two patients are alike, whether it’s experiencing symptoms differently or receiving different treatments,” he said, adding, “what it takes from you is different.”

Argenx hopes the films educate not only the MG community but also the general public and healthcare professionals about the serious impact of the often hidden and difficult-to-diagnose disease.

Woods said something a patient once told him has stuck with him over the years.

“She said, ‘People think we’re faking symptoms, but in reality, we’re faking so you don’t see the symptoms,’” he said.

He also thinks about what Glenn the former firefighter says in the movie: that on a good day he is 70% of who he used to be, but on a bad day, he is only 10%.

About 60,000 people in the U.S. have MG, which causes a variety of symptoms. Major muscle weakness is the most common, although symptoms vary. Argenx anticipates filing a biologics license application for its candidate efgartigimod to treat generalized MG with the FDA later this year.

The phase 3 trial of efgartigimod recently hit its primary endpoint, putting Argenx on track for a fall filing and an anticipated drug launch in the U.S. in 2021.

The only other drug approved in the past several decades to treat MG is Alexion’s Soliris. It picked up an FDA nod for generalized myasthenia gravis in 2017 to treat muscle weakness symptoms.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026